The global consensus programme to define and risk-stratify immunosuppression

The challenge

The term immunosuppression is generally accepted as referring to those who, either due to a specific diagnosis, procedure, or course of medication, do not mount a sufficient immune response to infection and onward disease. However, confusion around the exact conditions that involve immunosuppression and their vulnerability to COVID-19 infection has created international rifts in how these patients are monitored and managed. This risks patient safety.

Managed by the Nuffield Department of Primary Care Health Sciences at the University of Oxford, the inaugural UK eDElphi STudy to DefINe and Risk-Stratify ImmunosupprESsion (DESTINIES Study) was founded to address these inconsistencies and, in so doing, better protect those who are immunosuppressed from the ongoing threat of COVID-19.